Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.624686/full |
| _version_ | 1818337262333591552 |
|---|---|
| author | Tae Nakano-Tateno Kheng Joe Lau Justin Wang Cailin McMahon Yasuhiko Kawakami Yasuhiko Kawakami Toru Tateno Takako Araki |
| author_facet | Tae Nakano-Tateno Kheng Joe Lau Justin Wang Cailin McMahon Yasuhiko Kawakami Yasuhiko Kawakami Toru Tateno Takako Araki |
| author_sort | Tae Nakano-Tateno |
| collection | DOAJ |
| description | Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use. |
| first_indexed | 2024-12-13T14:52:25Z |
| format | Article |
| id | doaj.art-3ad90c9065a444ceac4e3c5dd9d52e87 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-13T14:52:25Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-3ad90c9065a444ceac4e3c5dd9d52e872022-12-21T23:41:18ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-03-011210.3389/fendo.2021.624686624686Multimodal Non-Surgical Treatments of Aggressive Pituitary TumorsTae Nakano-Tateno0Kheng Joe Lau1Justin Wang2Cailin McMahon3Yasuhiko Kawakami4Yasuhiko Kawakami5Toru Tateno6Takako Araki7Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, CanadaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, United StatesDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, United StatesDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, United StatesDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, United StatesStem Cell Institute, University of Minnesota, Minneapolis, MN, United StatesDivision of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, CanadaDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, United StatesUp to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.https://www.frontiersin.org/articles/10.3389/fendo.2021.624686/fullnon-surgical therapyTemozolomideCAPTEMPRRT (Peptide Receptor Radionuclide Therapy)aggressive pituitary tumorspituitary carcinomas |
| spellingShingle | Tae Nakano-Tateno Kheng Joe Lau Justin Wang Cailin McMahon Yasuhiko Kawakami Yasuhiko Kawakami Toru Tateno Takako Araki Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors Frontiers in Endocrinology non-surgical therapy Temozolomide CAPTEM PRRT (Peptide Receptor Radionuclide Therapy) aggressive pituitary tumors pituitary carcinomas |
| title | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors |
| title_full | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors |
| title_fullStr | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors |
| title_full_unstemmed | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors |
| title_short | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors |
| title_sort | multimodal non surgical treatments of aggressive pituitary tumors |
| topic | non-surgical therapy Temozolomide CAPTEM PRRT (Peptide Receptor Radionuclide Therapy) aggressive pituitary tumors pituitary carcinomas |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.624686/full |
| work_keys_str_mv | AT taenakanotateno multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT khengjoelau multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT justinwang multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT cailinmcmahon multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT yasuhikokawakami multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT yasuhikokawakami multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT torutateno multimodalnonsurgicaltreatmentsofaggressivepituitarytumors AT takakoaraki multimodalnonsurgicaltreatmentsofaggressivepituitarytumors |